BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Press Releases

  Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

  April 28, 2025

   · 

  1 min read
• Press Releases

  ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

  April 28, 2025

   · 

  6 min read
• Press Releases

  Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer

  April 28, 2025

   · 

  11 min read
• Press Releases

  Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

  April 28, 2025

   · 

  10 min read
• Press Releases

  Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system

  April 28, 2025

   · 

  6 min read
• Press Releases

  CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

  April 28, 2025

   · 

  7 min read
• Press Releases

  New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott’s Volt™ PFA System for Patients with AFib

  April 28, 2025

   · 

  4 min read
• Press Releases

  Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease

  April 28, 2025

   · 

  2 min read
• Press Releases

  New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

  April 28, 2025

   · 

  7 min read
• Press Releases

  KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

  April 28, 2025

   · 

  19 min read